ASTRAZENECA PLC ADR

NASDAQ: AZN (Astrazeneca PLC)

最近更新时间: 23 Sep, 5:02PM

77.14

-1.24 (-1.58%)

  • 1天 -1.58%
  • 5天 14.45%
  • 1月 20.04%
  • 6月 -2.21%
  • 今年至今天 12.78%
  • 1年 16.35%
  • 5年 54.62%
前收盘价格 78.38
收盘价格 77.24
成交量 3,788,214
平均成交量 (3个月) 4,388,519
市值 239,634,644,992
市盈率 (P/E TTM) 37.45
预期市盈率 (P/E Forward) 14.58
价格/销量 (P/S) 4.16
股市价格/股市净资产 (P/B) 5.19
52周波幅
60.47 (-21%) — 87.68 (13%)
利润日期 12 Nov 2024
股息率 (DY TTM) 1.93%
营业毛利率 12.68%
营业利益率 (TTM) 20.40%
稀释每股收益 (EPS TTM) 2.07
季度收入增长率 (YOY) 18.00%
季度盈利增长率 (YOY) 4.00%
总债务/股东权益 (D/E MRQ) 77.47%
流动比率 (MRQ) 0.930
营业现金流 (OCF TTM) 11.33 B
杠杆自由现金流 (LFCF TTM) 9.51 B
资产报酬率 (ROA TTM) 8.50%
股东权益报酬率 (ROE TTM) 16.66%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 看涨 看涨
Drug Manufacturers - General (全球的) 看涨 看涨
股票 Astrazeneca PLC 看涨 看涨

AIStockmoo 评分

1.3
分析师共识 2.0
内部交易活动 NA
价格波动 2.0
技术平均移动指标 1.5
技术振荡指标 -0.5
平均 1.25

相关股票

股票 市值 DY P/E（TTM） P/B
AZN 240 B 1.93% 37.45 5.19
SNY 120 B 8.54% 25.24 1.55
AMGN 143 B 3.38% 34.01 18.81
GILD 113 B 3.40% 1,005.44 6.21
GRFS 6 B - 32.20 0.830
BIIB 23 B - 14.35 1.31

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Growth
机构持股比例 16.76%

该时间范围内无数据。

该时间范围内无数据。

  • 3M
日期 类型 细节
18 Dec 2024 CNBC Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
12 Dec 2024 公告 Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development
11 Dec 2024 公告 LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
09 Dec 2024 公告 Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
08 Dec 2024 公告 Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
06 Dec 2024 公告 IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
05 Dec 2024 公告 IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
25 Nov 2024 公告 TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
20 Nov 2024 公告 AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
18 Nov 2024 公告 GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
12 Nov 2024 公告 AstraZeneca’s 9M and Q3 2024 results
12 Nov 2024 公告 AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
08 Nov 2024 公告 TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
07 Nov 2024 公告 AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
18 Oct 2024 CNBC Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
07 Oct 2024 公告 AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
03 Oct 2024 公告 CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
02 Oct 2024 公告 Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
01 Oct 2024 公告 ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
26 Sep 2024 公告 TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
23 Sep 2024 公告 Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
显示更多
股息率 (DY TTM) 1.93%
5年平均股息收益率 2.46%
股息支付比率 71.57%
预计下次股息支付 Mar 2025
除息日 公告日期 支付日期 详情
09 Aug 2024 25 Jul 2024 09 Sep 2024 0.5 现金
22 Feb 2024 08 Feb 2024 25 Mar 2024 0.985 现金
10 Aug 2023 28 Jul 2023 11 Sep 2023 0.465 现金
23 Feb 2023 09 Feb 2023 27 Mar 2023 0.985 现金
11 Aug 2022 29 Jul 2022 12 Sep 2022 0.465 现金
24 Feb 2022 10 Feb 2022 28 Mar 2022 0.985 现金
12 Aug 2021 29 Jul 2021 13 Sep 2021 0.45 现金
25 Feb 2021 11 Feb 2021 29 Mar 2021 0.95 现金
13 Aug 2020 30 Jul 2020 14 Sep 2020 0.45 现金
27 Feb 2020 14 Feb 2020 30 Mar 2020 0.95 现金
08 Aug 2019 29 Jul 2019 09 Sep 2019 0.45 现金
28 Feb 2019 14 Feb 2019 27 Mar 2019 0.95 现金
09 Aug 2018 26 Jul 2018 10 Sep 2018 0.45 现金
15 Feb 2018 02 Feb 2018 19 Mar 2018 0.95 现金
09 Aug 2017 28 Jul 2017 11 Sep 2017 0.45 现金
15 Feb 2017 02 Feb 2017 20 Mar 2017 0.95 现金
10 Aug 2016 28 Jul 2016 12 Sep 2016 0.45 现金
17 Feb 2016 05 Feb 2016 21 Mar 2016 0.95 现金
12 Aug 2015 30 Jul 2015 14 Sep 2015 0.45 现金
18 Feb 2015 09 Feb 2015 23 Mar 2015 1.9 现金
13 Aug 2014 31 Jul 2014 15 Sep 2014 0.9 现金
19 Feb 2014 07 Feb 2014 24 Mar 2014 1.9 现金
14 Aug 2013 01 Aug 2013 16 Sep 2013 0.9 现金
13 Feb 2013 31 Jan 2013 18 Mar 2013 1.9 现金
08 Aug 2012 26 Jul 2012 10 Sep 2012 0.9 现金
15 Feb 2012 02 Feb 2012 19 Mar 2012 1.95 现金
04 Aug 2011 28 Jul 2011 12 Sep 2011 0.85 现金
02 Feb 2011 27 Jan 2011 14 Mar 2011 1.85 现金
04 Aug 2010 29 Jul 2010 13 Sep 2010 0.7 现金
03 Feb 2010 28 Jan 2010 15 Mar 2010 1.71 现金
05 Aug 2009 30 Jul 2009 14 Sep 2009 0.59 现金
04 Feb 2009 29 Jan 2009 16 Mar 2009 1.5 现金
06 Aug 2008 31 Jul 2008 15 Sep 2008 0.55 现金
07 Feb 2008 04 Feb 2008 17 Mar 2008 1.35 现金
08 Aug 2007 27 Jul 2007 17 Sep 2007 0.52 现金
07 Feb 2007 01 Feb 2007 19 Mar 2007 1.23 现金
09 Aug 2006 27 Jul 2006 18 Sep 2006 0.49 现金
08 Feb 2006 02 Feb 2006 20 Mar 2006 0.92 现金
10 Aug 2005 29 Jul 2005 19 Sep 2005 0.38 现金
09 Feb 2005 27 Jan 2005 21 Mar 2005 0.645 现金
11 Aug 2004 22 Jul 2004 20 Sep 2004 0.295 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2024 1.49 2 1.93
2023 1.45 2 2.15
2022 1.45 2 2.14
2021 1.40 2 2.40
2020 1.40 2 2.80
2019 1.40 2 2.81
2018 1.40 2 3.69
2017 1.40 2 4.04
2016 1.40 2 5.12
2015 2.35 2 6.92
2014 2.80 2 7.96
2013 2.80 2 9.43
2012 2.85 2 12.06
2011 2.70 2 11.67
2010 2.41 2 10.44
2009 2.09 2 8.91
2008 1.90 2 9.26
2007 1.75 2 8.17
2006 1.41 2 5.27
2005 1.03 2 4.22
2004 0.295 1 1.62
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2024 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票